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Abstract 
Platelet-rich plasma (PRP) commonly refers to blood products which contain a higher platelet (PLT) concentration 
as compared to normal plasma. Autologous PRP has been shown to be safe and effective in promoting the natural 
processes of soft tissue healing or reconstruction in humans and horses. Variability in PLT concentration has been 
observed in practice between PRP preparations from different patients or from the same individual under different 
conditions. A change in PLT concentration could modify PRP efficacy in routine applications. The aim of this study was 
to test the influence of environmental, individual and agonistic variables on the PLT concentration of PRP in horses. 
Six healthy Standardbred mares were exposed to six different variables with a one-week washout period between 
variables, and PRP was subsequently obtained from each horse. The variables were time of withdrawal during the day 
(morning/evening), hydration status (overhydration/dehydration) treatment with anti-inflammatory drugs and train-
ing periods on a treadmill. The platelet concentration was significantly higher in horses treated with a non-steroidal 
anti-inflammatory drug (P = 0.03). The leukocyte concentration increased 2–9 fold with respect to whole blood in the 
PRP which was obtained after exposure to all the variable considered. Environmental variation in platelet concentra-
tion should be taken into consideration during PRP preparation.
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Findings
Platelet-rich plasma (PRP) is a suspension of platelets, 
white blood cells (WBCs) and a minimal number of red 
blood cells in a small volume of plasma. The ideal con-
centration of cellular components in PRP products has 
not yet been established and is the topic of ongoing 
research and debate [1–3].
The currently accepted benchmark for PRP used in 
human medicine is a platelet (PLT) concentration of 
at least a four/five-fold increase over whole blood or a 
platelet count range between 150 × 109/l and 350 × 109/l 
[2, 4]. In horses, where the baseline concentration of 
platelets is 200 × 109/l [5], a benchmark of 250 × 109/l 
has commonly been used for equine PRP [6].
The preparation method may significantly affect the 
concentrating capabilities of some PRPs [6]. The benefits 
of a high PLT concentration in PRP (4358 ± 265 × 109/l) 
to stimulate bone regeneration in human medicine has 
been documented [7].
The variability in the PLT concentration between 
preparations from different patients or from the same 
individual under different conditions could hamper the 
establishment of the most effective PLT concentration 
and PLT/WBC ratio in experimental studies, or reduce 
the PRP efficacy in routine applications. In an animal 
model using rabbits, the hematocrit, among other hae-
matological variables, was found to be the main hemato-
logical parameter influencing the PRP concentration [8]. 
In horses, “intrinsic” individual factors, such as breed, 
age and gender, have been demonstrated to play a role in 
PRP composition [1]. No data have been reported regard-
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The present study was designed to analyse some envi-
ronmental and intrinsic factors which could influence 
the PRP platelet concentration in equine medicine. The 
following parameters were considered: time of day, over-
hydration, dehydration, anti-inflammatory drug (NSAID) 
therapy and exercise. This study was approved by the eth-
ics committee of the University of Bologna in accordance 
with European Economic Community Council Direc-
tive 86/609, adopted by the Italian Government (D.L. 
27/01/1992 no. 116).
Six healthy Standardbred mares were used for the 
study. The median age of the horses was 16  years (12–
18  years) and the median weight was 480  kg (range 
370–520 kg).
The entire protocol was carried out over nine weeks. 
Every week, each horse was scheduled randomly for one 
variable with respect to the others. The variables were:
Time of day the blood sampling was carried out at 7.00 
a.m. (DAY) and at 7.00 p.m. (NGH). The platelet and the 
WBC data obtained from the hematological evaluation 
before any treatment were considered to be the control 
PLT and the WBC blood values (Table 1).
Overhydration (HYD) Blood sampling was carried out 
before and after an overload of Ringer Lactate; intrave-
nous administration was stopped when the urine specific 
gravity was equal to or less than 1020.
Dehydration (DHY) Blood sampling was carried out 
before and after withholding water until an increase in 
serum creatinine and serum albumin above our labora-
tory reference interval (RI) [creatinine RI: 0.90–1.50 mg/
dL; albumin RI: 2.90–3.70 g/dL] was observed.
NSAID drug therapy Blood sampling was carried out 
before and after anti-inflammatory therapy with ketopro-
fen (2 mg/kg intravenously) every 24 h for 5 days.
Exercise (EXE) Blood sampling was carried out before 
and after standardised exercise training consisting of 
3 min at 2 m/s followed by 3 min at 4 m/s, and then 3 min 
at 6 m/s on a treadmill. This program was carried out for 
9 days; on the 10th day, a speed test was carried out by 
adding 3 min at a speed of 8 m/s to the previous protocol.
Blood was collected in the morning (unless indicated 
differently) with a 1  week washout interval between 
experiments (washout period exceeding the detection 
time for Fédération Equestre Internationale of 96 h). Each 
of the six horses underwent each treatment randomly. 
Before the first PRP processing, a 1 ml aliquot of whole 
blood was saved for analysis of baseline values.
In each horse, 450  ml of blood was harvested from 
the jugular vein and was stored in double transfusion 
bags containing a citrate–phosphate-dextrose solution 
with adenine (CPDA-1) (Terumo BCT, Roma, Italy). 
The separation of the blood cells was carried out within 
3  h after the sampling using a refrigerated laboratory 
centrifuge (Heraeus Cryofuge 6000, Thermo scientific, 
Waltham, USA). Centrifugation was first performed 
at 350g for 20  min at 22  °C in order to obtain separa-
tion of the erythrocytes and the WBCs from the plasma 
and the platelets. The satellite bag underwent a second 
centrifugation at 3300g for 10  min at 22  °C to obtain 
PRP, as a turbid fraction, and platelet-poor plasma. 
The PRP was transferred to a 1.5 ml tube under sterile 
conditions.
Data are reported as medians and ranges. In the vari-
able groups, the PLT and the WBC concentrations were 
compared using the base values (whole blood) and the 
concentrations obtained after exposition to the variables; 
moreover, a comparison between the groups was carried 
out using a Wilcoxon paired sample test (MedCalc 6.3). 
The results were considered statistically significant for 
P < 0.05.
As expected, the PRP preparation produced signifi-
cantly increased levels of both the PLT and the WBC 
concentrations as compared to whole blood after expo-
sure to all the variables. (Figures 1, 2).
Table 1 Platelet concentration and white blood cell count
Summary of the platelet concentration and white blood cell (WBC) count in whole blood in the different groups
Group: Time of day: The blood sampling was carried out at 7.00 a.m. (DAY) and at 7.00 p.m. (NGH); overhydration (HYD): the blood sampling was carried out before 
and after an overload of Ringer Lactate; dehydration (DHY): the blood sampling was carried out before and after withholding water; non-steroidal anti-inflammatory 
(NSAID) drug therapy: the blood sampling was carried out before and after anti-inflammatory therapy; exercise (EXE): the blood sampling was carried out before and 
after standardised exercise training
Platelet and WBC concentration count ( 109/L )
Group Platelet in whole blood median Platelet in whole blood range WBC in whole blood median WBC in whole blood range
DAY 149 119–156 8.605 7.21–10.53
NGH 133 106–187 8.81 6.71–9.38
HYD 100 70–190 7.195 5.81–7.67
DHY 138 51–227 8.58 7.34–9.97
NSAID 108 65–171 8.71 6.18–9.86
EXE 129 78–143 9.6 6.69–10.51
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The platelet concentration in the PRP was significantly 
higher in the horses treated with NSAIDs as compared 
to the DAY group (P  =  0.03) (Fig.  1). In all the PRPs 
obtained after exposure to the variables, the leukocyte 
concentration increased 2–9 fold with respect to the 
whole blood value. A higher WBC concentration was 
measured in the PRP of the DHY group as compared 
with the DAY group (Fig. 2) and this difference was sta-
tistically significant (P = 0.02).
The results demonstrated that the PLT concentration 
in PRP was significantly higher in horses treated with 
NSAIDs as compared to the DAY group. However, it was 
not possible to find any significant differences associ-
ated with the other variables. A 1 week washout period 
reduced the risk of the interference of residual drug in 
the blood before exposure to next variable.
A difference was detected between the DAY and the 
NGH sampling in the WBC concentration in the PRP 
(P  =  0.03). Clinicians should be aware that the effects 
of PRP are based not solely on PLT concentration, even 
though many of the reparative factors are contained in 
the PLTs. The optimal combination of each cellular com-
ponent in the PRP remains unknown and, since recent 
studies do not report ideal PLT or WBC concentrations, 
it is unknown which PRP preparation is best for each 
clinical indication [9].
This study demonstrated that the use of ketoprofen 
might affect the PLT concentration in PRP, probably due to 
the decreased platelet aggregation, as with other NSAIDs 
[8, 10]. Indeed, PLT aggregates have a higher sedimenta-
tion rate with respect to isolated PLTs leading to a posi-
tion closer to the cell pellet after centrifugation. This may 
cause a depletion of PLTs from the plasmatic component. 
It would be of pivotal importance to assess whether the 
reduced aggregation ability of the PLTs could further affect 
the release of the mediators and factors necessary for the 
PRP to be effective. The NSAID variable (ketoprofen), was 
considered due to its frequent use in horses. During PRP 
preparation, the presence of NSAIDs in the blood would 
prevent the production of tromboxane A2 by platelets 
since it is a strong platelet aggregating factor. This informa-
tion is crucial in order to know whether or not to suspend 
the NSAID treatment before PRP production. Different 
factors have been reported to influence the platelet con-
centration. In particular, the hematocrit has been found 
to reduce the platelet concentration [8] while, in female 
horses, the PLT concentration was higher than in male 
horses [1]. In the current study, six adult female Standar-
bred horses were chosen in order to reduce the number of 
intrinsic factors which could have influenced the results.
Optimisation of the PLT preparation should include 
understanding the role of WBCs regarding the clinical 
Fig. 1 Platelet concentration. Box plots of platelet concentration [109/l] in whole blood (WB) and platelet rich plasma (PRP) in each treatment group. 
The samples were obtained in each horse (six animals) at 7.00 a.m. (DAY) and at 7.00 p.m. (NGH), before and after an overload of Ringer Lactate 
(HYD), before and after withholding water (DHY), before and after treatment with non-steroidal anti-inflammatory drugs (NSAIDs), and before 
and after exercise training (EXE). Box plots show the median, upper and lower interquartile and range. The dashed lines represent the comparison 
between WB and PRP. The continuous line represents the pairwise correlations between the DAY group (control group) and the NSAID group. 
*(P = 0.03)
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effects attributed to PRP [11]. Leukocytes contain and 
produce biologically active catabolic or inflammatory 
cytokines which could influence the clinical outcome of 
a PRP application. Moreover the concentration of tumor 
necrosis factor alpha and interleukin-1-beta seems to be 
correlated with the neutrophil number in PRP [12].
Recent studies have demonstrated that WBC reduction 
is important for the success of PRP in some musculoskel-
etal applications [3, 13]. Our study demonstrated that the 
WBC concentration of the PRP of the DHY group was 
higher than the concentration found in the DAY group 
(P = 0.02). According to our experience and based upon 
the information available, dehydration should be cor-
rected before blood withdrawal for PRP preparation in 
order to avoid increased WBC content in the PRP.
Our study points out the fact that, in clinical studies 
involving PRP preparations, it is important to take envi-
ronmental factors into consideration as they may impact 
the expected PLT and WBC concentrations. In fact, both 
components could be influenced by individual external 
conditions in PRP preparations. Additional studies are 
necessary to investigate other variables and to confirm 
the results obtained for ketoprofen, also in sires/geldings, 
in other age groups and with other NSAIDs in order to 
definitively strengthen the conclusions of this study.
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